EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Risk of collagen-related disorders and neurological events among patients with uncomplicated urinary tract infection following short treatment with fluoroquinolones: a cohort study

Fanny S Mitrani-Gold iD, Shinyoung Ju, Myriam Drysdale, Anna Schultze, George Mu, John Logie

Antimicrobial Agents and Chemotherapy · 05.12.2024 · 68 (12)

DOI: 10.1128/aac.00690-24 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.12.2024. Verfasst von Fanny S Mitrani-Gold und 5 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Fluoroquinolones, Urinary Tract Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Studies of fluoroquinolone (FQ) safety across indications show increased collagen/neurological adverse event (AE) risk, yet patients still receive FQs for uncomplicated urinary tract infections (uUTIs). This retrospective, cohort study investigated the risk of collagen/neurological AEs of special interest (AESIs) with short-term FQ use versus standard-of-care antibiotics (trimethoprim–sulfamethoxazole [SXT], nitrofurantoin [NTF]) among female outpatients with uUTIs. This study was conducted between December 2009 and 2019 using Optum’s de-identified Clinformatics Data Mart Database. Adjusted absolute risks were calculated for composite/collagen/neurological AESIs (Kaplan–Meier cumulative hazards, after applying stabilized inverse probability of treatment weighting [sIPTW]). Adjusted hazard ratios were generated (sIPTW Cox proportional hazard modeling). Overall, 954,777 patients were included: FQ ( n = 386,537 [40.5%]); SXT ( n = 237,120 [24.8%]); NTF ( n = 314,585 [32.9%]). Adjusted absolute risk range for collagen/neurological AESIs was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesUrinary Tract InfectionsAnti-Bacterial AgentsHumansFemaleRetrospective StudiesMiddle AgedAdultAgedTrimethoprim, Sulfamethoxazole Drug CombinationNitrofurantoinNervous System DiseasesCollagen DiseasesProportional Hazards ModelsCohort Studies

Stichwörter der Autor:innen

adverse events of special interestantibioticscollagen eventsfluoroquinolonesneurological eventsriskstandard-of-careuncomplicated urinary tract infection

Substanzen

FluoroquinolonesAnti-Bacterial AgentsTrimethoprim, Sulfamethoxazole Drug CombinationNitrofurantoin

Autor:innen und Institutionen

  • GSK, Collegeville, Pennsylvania, USA.
  • GSK, London, United Kingdom.
  • London School of Hygiene and Tropical Medicine, London, United Kingdom.

ORCID-Profile: Fanny S Mitrani-Gold

Förderung

  • GSK

Zitieren

APA

Mitrani-Gold, F. S., Ju, S., Drysdale, M., Schultze, A., Mu, G., & Logie, J. (2024). Risk of collagen-related disorders and neurological events among patients with uncomplicated urinary tract infection following short treatment with fluoroquinolones: a cohort study. Antimicrobial Agents and Chemotherapy, 68(12). https://doi.org/10.1128/aac.00690-24

Vancouver

Mitrani-Gold FS, Ju S, Drysdale M, Schultze A, Mu G, Logie J. Risk of collagen-related disorders and neurological events among patients with uncomplicated urinary tract infection following short treatment with fluoroquinolones: a cohort study. Antimicrobial Agents and Chemotherapy. 2024;68(12). doi:10.1128/aac.00690-24

BibTeX
@article{MitraniGold2024,
  author = {Mitrani-Gold, Fanny S and Ju, Shinyoung and Drysdale, Myriam and Schultze, Anna and Mu, George and Logie, John},
  title = {Risk of collagen-related disorders and neurological events among patients with uncomplicated urinary tract infection following short treatment with fluoroquinolones: a cohort study},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {12},
  doi = {10.1128/aac.00690-24}
}
Kostenlos starten →